

Keyword index to Volume 81

- Acetaminophen 542
N-Acetyltransferase 1 537
N-Acetyltransferase 2 537
Actin 393
Acute lymphoblastic leukaemia 175
Acute myeloid leukaemia 900
Adenocarcinoma 159
Adenoma 232
Adenovirus vectors 277
Adolescence 167
Adrenal cortex 684
Adrenocortical tumours 300
Advanced non-small-cell lung cancer 846
Adverse effects 336
Aetiology 898, 907
Affective disorders 907
Age-period-cohort analysis 152
Age-period-cohort models 159
Agreements 87
ALA cream 13
ALA lotion 13
ALA-PDT 13
Alcohol abuse 907
Alkaline sphingomyelinase 232
Allelic imbalance 1111
5-Aminolaevulinic acid 13
Amplification 1174, 1410
Analgesics 542
Anatomic sites 528
Androgens 28
Androgens, synthesis of 622
Androgen ablation 242
Androgen receptors 242, 672
Angiogenesis 54, 225, 354, 647, 1088, 1335, 1363, 1398
Angiosarcomas 532
Angiostatin 1269
Animal tumour models 638
Anthracyclines 24
Anthropometry 1257
Anti-angiogenesis 1269
Anti-vascular shutdown 1318
Antibodies 769
Antimicrobial peptides 393
Antisense interleukin-2 oligonucleotides 822
Antisense-EGFR 994
AP-2 133
APC protein 850
Apoptosis 277, 294, 387, 423, 520, 592, 747, 822, 952, 981, 1274, 1285, 1294
Arsenic trioxide 796
Asia, south east 893
Aspirin 294, 542
Astrocytomas 835
Atomic bomb survivors 1248
ATPase 269
Autoantibodies 702
Autocrine regulation 1335
Automatic quantification 1363
Azolyl steroids 622
Background transcription 870
BAG-1 1042
bcl-2 252
Bcl-2 387, 860, 1042
Bcl-x(L) 387
Benzamides 981
Berberine 416
Bi-specific monoclonal antibodies 431
Bicalutamide 242
Biological factors 925
Biomarkers 1222, 1238
Bioreductive drugs 1127
Biotinylated anti-CD3 Fab fragments 431
Bisdioxopiperazine 800
BK virus 898
Bladder cancer 537, 832
B-lymphoma cells, human 43
Body mass indices 890
Bombesin receptors 966
Bone marrow 1213
Brain tumours 1371
BRCA1 179
BRCA1 503
BRCA2 179
BRCA2 503
Breast cancer 225, 287, 316, 342, 387, 440, 532, 592, 690, 702, 850, 912, 1002, 1042, 1142, 1248, 1304, 1385
Breast cancer cells 252
Breast neoplasms 167, 490
Breast size 1257
Bromodeoxyuridine 404
Buthionine sulphoximine 796
C1311 367
CA19-9 769
CA 125 662
Cachexia 80
Calcium 219
cAMP analogues 1134
Cancer chemotherapy 69
Cancer invasion 721
Cancer risks 672
Cancer screening 554
Cancer testis antigens 1080
Cancer therapy 966
Cancer xenografts, human 203
Carboplatin 336
Carcinomas 592, 1059, 1363
Carcinomas, human 822
Cardiotoxicity 24
Carotenoids 1234
Case-control studies 62, 559, 890
Caspases 294, 592
 β -Catenin 1392
Cathepsin-B 510
Cathepsin-D 1385
CD34 808
Cell adhesion 381
Cell cultures 814
Cell cycles 808, 1285
Cell cycle checkpoints 959
Cell cycle regulators 696
Cell lines 814
Cell proliferation 712
Cell transformation 790
Cell-cell interaction 1142
c-erbB-2 1385
c-erbB-2 oncogenes 790
Cervical cancer 95, 108, 159, 554, 989
Cervical dysplasia 1234
Cervical scrapings 114
CGH 300, 1328, 1410
CHART 1196
Chemotherapy 75, 316, 336, 469, 484, 520, 835, 860, 1022, 1031, 1213, 1280
Chemotherapy, high-dose sequential 449
Chemotherapy responses 1017
Childhood 900
Childhood cancer 549
Childhood leukaemia 144
Children 175, 336, 835
Chromogranin A 667
Chromosomal aberrations 1328
Chromosome 3 684
Chromosome 9 684
Chromosome 17q 1402
Chromosome 22 1150
Chromosome X 684
Cigarette smoking 537
Cimetidine 1356
Circulating cancer cells 1066
Circulating epithelial cells 832
Circulating tumour cells 1165
Cisplatin 28, 95, 469, 1294
Clinical outcomes 696, 1174
Clinical trials 1356
Clonogenicity 756
c-MET 43
c-myc 1385
Confluent fibroblast layers 934
Cohort effects 152
Collagen 654
Collagen gene expression 1142
Colon adenocarcinoma cell lines 1285
Colon cancer 232, 237, 294, 600, 1274
Colon tumours 1318
Colorectal cancer 62, 122, 133, 190, 287, 305, 367, 874, 1009, 1116
Colorectal cancer, human 496
Combination regimens 609
Combined modality 1206
Combretastatin A-4 1318
Concurrent chemoradiation in NSCLC 310
Core biopsy 1088
Cost-effectiveness analysis 1243
COX-2 1274
CPT-11 95, 440
CT antigens 1162

- CTLs 342, 881
 Cultures 1344
 Cyclic A 1017
 Cyclic D1 127
 Cyclin D 705
 Cyclin D1 1174
 Cyclin-dependent kinase 705
 CYP17 polymorphisms 141
 Cystoprostatectomy 832
 Cytochrome P450 reductase 1127
 Cytogenetics 6
 Cytokeratin 8 769
 Cytokeratin 20 870
 Cytokines 359
 Cytokine-induced killer cells 1009
 Cytological screening 159
 Cytoplasm 1174
 Cyto reduction 733
 Cytotoxicity 367, 1022, 1127
- DCIS 1410
 Dendritic cells 1280
 Dialysis *in vitro* 330
 Diet 1234, 1238
 Differentiation markers 855
 Directly streptavidinylated antibodies 431
 Dissemination 43
 Distinct entities 586
 Divalent Fab' 972
 DNA damage 1127
 DNA intercalation 367
 DNA mutations 409
 DNA repair 800
 Docetaxel 457, 609
 Docosahexaenoic acid 80, 1238
 Dose escalation 1022
 Dosimetry 972
 Doxorubicin 966
 Drug binding 783
 Drug delivery systems 1155
 Drug targeting 404
 Ductal carcinoma *in situ* 702
- Early relapse 1385
 E-cadherin 1103, 1392
 ED-B fibronectin hybridization *in situ* 1071
 EGF 1134
 Eicosapentaenoic acid 80, 1238
 Electromagnetic fields 377
 ELISA 490
 Endotoxins 1311
 Ependymoma 1150
 Epidemiology 62, 144, 672, 900
 Epstein-Barr virus 1182
 Establishment 814
 Esthesioneuroblastoma 586
 Evaluations 912
 Experimental metastasis 756
 External ear 528
 Extracellular matrix 1142
 Extracellular signal regulated kinase 1116
 Extraction 600
- False-negative tests 305
 Familial clustering 1150
 FAP 232
 α -Fetoprotein 1188
 Fibronectin isoforms 1071
 FISH 1165, 1328
 Fish oil 80, 440
- Flavopiridol 269
 Fluorescence 600
 Fluorouracil derivatives 484
 Free fraction 330
- G1 checkpoints 696
 Gastric cancer 19, 484, 647, 1356, 1392
 G-CSF 1031
 Gemcitabine 609, 846
 Gene transfer 1009, 1122
 Gene-specific repairs 1294
 Genetics 672
 Genetic markers 1002
 Genetic susceptibility 179, 1262
 Geographic variations 1262
 Germlines 409
 GF120918 942
 Glioblastoma 994
 Glioma 835, 1371
 Glucose 1,6-bisphosphate 219
 Glucosylceramide 423
 Glutathione 75, 796, 989
 Glycolysis 219
 Glycosylation 1188
 Granzyme B 881
 Growth inhibition 952
- Haemangiosarcomas 532
 Haematopoiesis 808
 Haemocult II^R 305
Haemophilus influenzae 175
 H2-Antagonists 1356
 HBsAg carriers 69
 HBV profiles 69
 Head and neck cancer 323, 457, 1196
 Head and neck tumours 677
 Hearts, chicken 934
 Hepatocellular carcinoma 393, 747, 814, 1188
 Hepatocyte growth factor 721
 HER2/neu 1419
 Hexokinase 219
 HGF 194
 HGF/SF 43
 hGPR 966
 HHV-8 893
 High-dose sequential chemotherapy 449
 Histological grades 167
 Histology 152
 HIT genes 874
 HLA 342
 hNMBR 966
 Hodgkin's disease 476, 1182
 Hormone analogues 966
 HPV 114
 HT-29 294
 HT-29 cells 367
 Human topoisomerase I 800
 Human cultured dendritic cells 1280
 Human herpesvirus-8 893
 Humanized monoclonal antibodies 1419
 Hybrid capture 554
 Hybridization *in situ* 496, 712
 17 α -Hydroxylase/C_{17,20}-lyase inhibitors 622
 Hypermethylation 677
 Hypoxia 989, 1127
- ICE 277, 1031
 I1307K 850
 Image analysis 1363
- Image cytometry 989
 Imbalances 684
 Immortalization 377
 Immunoassays 122
 Immunoconjugates 1155
 Immunocytochemistry 404, 1213
 Immunohistochemistry 127, 747, 1080
 Immunotherapy 1080, 1280
In situ hybridization 496, 712
In vitro dialysis 330
 Induction chemotherapy 310
 Infection 549
 Inflammatory breast cancer 449
 Inoperability 1031
 Interleukin-1 β 277
 Interleukin-1ra 277
 Interleukin-2 822, 1009
 Interleukin-2/interleukin-2R pathways 822
 Interleukin-6 690
 Interleukin-8 647
 International studies 463
 Interphase cytogenetics 684
 Interstitial photodynamic therapies 631
 Interval cancer 912
 Intestinal side-effects 440
 Intraluminal seeding 6
 Intramedullary tumours 835
 Invasion 654, 774
 Ionizing radiation 959
 Irinotecan 440
 (Iso)flavonoids 269
- Japan 1248
 JC virus 898
 JM216 1294
- Kaposi's sarcoma associated herpesvirus 893
 K⁺-ATPase 28
 Ki-67 747, 1017
 Kinase activities 705
 KN62 959
 Knock out mice 359
 KSHV 893
- Laminin isoforms 1071
 Leukaemia 549, 833, 898, 1162, 1398
 Leukaemia, acute lymphoblastic 175
 Leukaemia, acute myeloid 900
 Lipopolysaccharides 1311
 Liver metastasis 600
 LNCaP cells 242, 622
 Lobular breast cancer 1103
 Locally advanced cancer 1031
 Locoregional recurrence 1385
 LOH 108, 503, 677, 1103, 1111, 1371, 1410
 Loss of heterozygosity 108, 503, 677, 1103, 1111, 1371, 1410
 Luminometric immunoassays 122
 Lung cancer 705, 1127, 1243
 Lung surgery 721
 Lymphangiogenesis 54
 Lymphangiosarcomas 532
 Lymphocyte function 1182
 Lymphoedemas 532
 Lymphomas 1009
 B-Lymphoma cells, human 43
 Lysosomes 367
 Macrophages 37, 496
 MACS 1165

- Magnetic resonance imaging 616, 638
 Male breast cancer 141
 Malignant mesothelioma 54, 1111, 1344
 Mammalian cells 377
 Mammary cancer 409, 1335
 Mammary tumours 194
 Mammographic parenchymal patterns 1257
 MAPK 1134
 Marimastat 19
 Markers 741
 Mastectomy 1222
 Matrigel 934
 Matrix metalloproteinases (MMPs) 19, 287, 774
 MCP-1 855
 MEK 1116
 Melanomas 219, 774, 918, 1066
 Meningioma 381
 Menopause 225
 MES-Dx5 cells 942
 [¹³¹I]-Metaiodobenzylguanidine 1378
 Metallothionein 712
 Metastasis 287, 316, 712, 774, 814, 832, 1274, 1311
 Metastasis-associated factors 814
 Metastatic potential 756
 Methotrexate 316, 1037
 MHC class I 881
 MHC class II 808
 MIA 1066
 β_2 -Microglobulin 881
 Micrometastases 870, 1002, 1213
 Microsatellites 1371
 Microsatellite instability 108, 190
 Microsatellite marker analysis 1111
 Microvessels 484
 Microvessel count 1088
 Microvessel density 1363
 Minimally invasive debulking 631
 Mismatched DNA 212
 Mitoxantrone 316
 MMP 1274
 MN/CA IX/G250 antigens 741
 MN/CA9/G250 genes 741
 Models 1243
 Molecular analysis 586
 Molecular cytogenetics 1328
 Monoclonal antibodies 1155
 Monoclonality 6
 MRP1 269
 MSI 108, 190
 mTHPC 37
 MTS 1280
 MUC1 mucin 431
 Multidrug resistance 269, 423, 783, 942, 1304
 Multifocal uroepithelial carcinomas 6
 Multiple myeloma 952
 Murine tumours 1311
 Mutations 237, 1103
 Myelodysplasia 1398
 Myeloma 1162
 Myofibroblasts 1071

 NADPH 1127
 Nasopharyngeal carcinoma 1122
 Neoadjuvant chemotherapy 95, 1206
 Neoplasms 684
 Neoplasms, breast 907
 Neoplasm staging 167

 Nephrotoxicity 336
 Neuroblastoma 1378, 1402
 Neuroendocrine carcinoma 1351
 Neurotic disorders 907
 NF κ B 981
 Nipple aspirate fluid 1222
 Nitric oxide 37
 NK cells 881
 nm23 469
 Node-negative breast carcinoma 727
 Non-Hodgkin's lymphoma 144, 860
 Non-seminomatous germ cell tumours 1188
 Non-small-cell lung cancer 127, 510, 769, 1031
 Non-small-cell lung cancer, advanced 846
 Non-small-cell lung cancer cell lines 609
 Non-small-cell lung cancer primary cultures 609
 Non-specified abuse 907
 Non-steroidal anti-inflammatory drugs 62, 542
 NSAIDs 62, 542
 Nucleus 1174
 Nude rats 1344
 Nutritional supplementation 80

 Obesity 890
 Oesophageal cancer 712
 Oesophageal squamous cell carcinoma 469
 17 β -Oestradiol 387
 Oestrogen 918
 Oestrogen receptors 1042
 Oestrogen replacement therapy 559
 Oncofetal extracellular matrix 1071
 Oncogene amplification 1328
 Oral, gastric and colon cancer cells 416
 Oral carcinoma 881, 1022
 Oral contraceptives 918
 Oral squamous cell carcinoma 1071
 Orthotopic transplantation 934
 Orthotopic tumours 1318
 Ovarian cancer 152, 179, 631, 662, 733, 790, 855, 1174, 1304
 Ovarian neoplasms 559, 654
 Overall survival 1385
 Overweight 890

 P4 952
 p16 677, 1122
 p21 133
 p21WAF1 959
 p21waf1 252
 p27Kip1 gene 1052
 p53 179
 p53 122, 133, 490, 702, 733, 959, 994, 1285
 p53, canine 409
 p53 mutants 212
 Paclitaxel 416
 Paediatric cancer 300
 PAK-200S 1304
 Pancreas-specific genes 350
 Pancreatic cancer 80, 350
 Papillomaviruses, human 554, 1234
 PEG-m-THPC 631
 Peptide 342
 Perforin 359
 Pericarditis 1037
 Period effects 152
 Peripheral blood 350
 Peritonitis 1037

 P-glycoprotein 783
 P-glycoprotein inhibitors 942
 pgp-170 416
 Phagocytosis 37
 Pharmacokinetic-pharmacodynamic relationships 330
 Pharmacokinetics 261, 1022, 1419
 Phase I studies 1419
 Phase I trials 760
 Phase II studies 310
 Phase II trials 457
 Phenacetin 542
 Phenotypic markers 952
 Phosphofructokinase 219
 Photodynamics 37
 Photodynamic therapies 261, 520, 600, 616
 Photosensitizers 261, 600
 Phthalocyanines 616
 Physiological factors 925
 Phyto-oestrogens 1248
 PK1-doxorubicin 99
 Plasma ultrafiltrate 330
 Plasminogen 1269
 Platinum-based therapies 75
 Pleural effusions 1059
 Pleurisy 1037
 PML 994
 Pneumonitis 1037
 Polymer conjugates 261
 Polymorphism 179, 850
 Population mixing 144
 Population pharmacokinetics 99
 Population-based screening 912
 pPNETs-ETs 586
 PR-39 393
 Preclinical therapies 609
 Preclinical toxicology 760
 Predictive assays 354
 Premenopause 167, 918
 Prevention 1243
 Primary chemotherapy 841
 Prodrug therapy 24
 Prognosis 122, 127, 133, 190, 469, 510, 662, 855, 1052, 1182, 1213
 Prognostic factors 667, 747
 Programme sensitivity 305
 Progression 127
 Prolactin-inducible proteins 1002
 Proliferation 1017
 Proliferative tumour cells 925
 Proportionate incidences 912
 Prostaglandin E₂ 194
 Prostate cancer 28, 242, 1052, 1269
 Prostate cancer, androgen-dependent 28
 Prostate cancer, androgen-independent 28
 Prostate-specific antigens 490, 1269
 Prostatic neoplasms 672, 1238
 Proteases 790
 Proteins 490
 Protein kinase A 1134
 Protein structures 1188
 Proteolysis 287
 Proteolytic cleavage 212
 Proto-oncogenes 237
 Proxy respondents 87
 Purification 1188

 17q24 1402
 Q-PCR-EIA 114
 Quality of life 87

- Questionnaires 87
 Quiescent tumour cells 925

 RAD51 503
 RAD52 503, 800
 RAD54 503
 Radiation 532
 Radioimmunotherapy 972
 Radiometabolic therapies 1378
 Radiosensitivity 959
 Radiotherapy 108, 323, 727, 841, 1196
 Radon 900
 Radon remediation 1243
 Raf-1 1116
 Randomization 1356
Ras 237
 Ras 1116
 Rat 631
 RB phosphorylation 808
 Rb protein 342, 705
 RBP-1 342
 Rectal neoplasms 463
 Registries 463
 Relapse 727
 Relapse-free survival 1385
 Renal cancer 1009
 Renal cell cancer 542, 741
 Renal function 336
 Residual diseases 860
 Resistance 252
 Response to chemotherapy 733
 Retinoic acid 381
 Retrospective cohort studies 144, 1351
 Retroviral transduction 43
 Reverse transcription polymerase chain reaction 350, 741, 870, 966, 1002, 1066
 RT-PCR 350, 741, 870, 966, 1002, 1066

 S phase 404
 S phase fractions 1017
 sCD30 1182
 Schedules 1285
 SCID mice 43, 622
 Screening 305
 Seascale 144
 Seasonality 549
 Second-line chemotherapy 846
 Secondary myeloid malignancy 476
 Selective COX-2 inhibitors 1274
 Seroprevalence 893

 Serosal complications 1037
 SF2 354
 s-ICAM-1 1182
 Sigma-2 receptors 925
 Single-chain antibodies 790
 Skin 528
 Small-cell lung cancer 667, 1206, 1213
 SN-38 1285
 Sodium 28
 Soft-tissue sarcomas 890, 1017
 Solid tumours 99
 Soluble receptors 203
 Somatostatin receptor 2 1402
 South-east Asia 893
 Southern blot analysis 1410
 Soya 1248
 Spinal cord tumours 835
 Squamous cell carcinoma 95, 159, 510, 528
 SSTR2 gene 1402
 Stage III cancer 122
 Staging 463
 Standardization 870
 Starting doses 760
 Steroids 690
 Steroid hormones 225, 783
 Stewart-Treves syndrome 532
 Superantigens 359
 Surgery 323, 1206, 1311
 Survival 323, 528, 727, 850
 Survival analysis 463
 Symptoms 1196
 Syndecan 393

 t(14;18) 860
 Targeting therapy 1155
 T-cells 359
 Testicular cancer incidence 1262
 Thymidine phosphorylase 484
 Thymomas 841
 Tirapazamine 1127
 Tissue inhibitor of matrix metalloproteinase (TIMP) 774
 TNF- α 37
 Tobacco 1228
 Tomudex 252
 Topical application 13
 Topoisomerase I 800
 Topotecan 1304
 Transcription 874
 Transfection 647

 Transitional cell carcinoma 638
 Transplantation 476, 1344
 Transurethral resection 832
 Treatments 1351
 Trivalent Fab' 972
 Tumorigenesis 232
 Tumorigenicity 756
 Tumours 874
 Tumours, human 75
 Tumour antigens 19
 Tumour cell growth 822
 Tumour cell shedding 756
 Tumour immunotherapy 431
 Tumour inhibition 966
 Tumour invasion 194, 381
 Tumour markers 667, 1059
 Tumour perfusion 756
 Tumour progression 242, 496
 Tumour-rejection antigens 1080
 Tumour responses 600
 Tumour suppressor genes 1103, 1122, 1150
 Tumour targeting 966, 972
 Tumour therapies 359
 Tumour vascular endothelium 1155
 Tumour vasculature 261
 Tumour-stromal interaction 194

 Ultrasound imaging 520
 United Kingdom 1243
 uPAR 203
 Urbanization 1262
 Urinary bladder 1363

 Vaccination 175
 Vascular endothelial growth factor 54, 225, 727, 1335, 1398
 VEGF 54, 225, 727, 1335, 1398
 VEGF receptors 1335
 VEGF-C 54

 Weight gain 167
 Western blotting 1080
 wnt genes 496
 Wortmannin 959

 Xenografts 774

 Yeast 800